secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xtant Medical Holdings, Inc. (XTNT)
CIK:        0001453593
Form:       8-K
Filed at:   2026-08-11T11:05:26+00:00
Accession:  0001493152-26-036979
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xtant Q2 revenue down 35% to $23M, net loss $9.4M, cuts FY guidance
-------------------------------------------------------------------

- Revenue $23.0M vs $35.4M YoY; net loss $9.4M vs income $3.6M.
- Adjusted EBITDA loss $2.7M vs +$6.9M; gross margin 57.9% vs 68.6%.
- FY2026 revenue guidance cut to $99-103M from $101-105M.
- Exclusive U.S. distribution deal with Dilon for HEMOBLAST Bellows; hired ~20-person sales team.
- Cash $9.9M, debt $23.0M, revolver availability $0.7M as of June 30, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453593/000149315226036979/0001493152-26-036979-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453593/000149315226036979/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-036979

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer